| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Vyne Therapeutics Inc. (VYNE) has 8 insiders with recent SEC Form 4 filings, including 3 buys and 0 sells. VYNE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 438.8K | $285.2K | - | |
| Other | 125.9K | $81.8K | - | |
| Other | 115.2K | $74.9K | - | |
| CFO | 103.8K | $67.5K | - | |
| Dir | 20.0K | $13.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 25, 2018 | Venbio Global Strategic Fund II L.P. | 10% Owner | Buy | 265,000 | $17.00 | $4,505,000.00 | New | |
| Jan 25, 2018 | Vivo Capital Viii, LLC57 | 10% Owner | Buy | 294,118 | $17.00 | $5,000,006.00 | New |